Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GW406381X

Known as: GW406381 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
An exposure–response model was used to characterize the pharmacokinetic‐pharmacodynamic relationship of GW406381, a COX‐2… Expand
2009
2009
UNLABELLED In this randomized, double-blind, placebo-controlled study, we evaluated the efficacy and safety of GW406381, an… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2009
2009
ObjectivesTo evaluate the efficacy and tolerability of 4 doses of GW406381, a cyclooxygenase-2 inhibitor, compared with placebo… Expand
2008
2008
CONTEXT GW406381 is an investigational, highly selective cyclooxygenase-2 (COX-2) inhibitor that is effective in animal models of… Expand
2008
2008
The objective of the present study was to explore the clinical efficacy and tolerability of GW406381, a cyclooxygenase‐2 (COX‐2… Expand
2007
2007
Abstract There are several lines of evidence to suggest that cyclooxygenase‐2 (COX‐2) plays an important role in the generation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2005
Highly Cited
2005
The pathogenic form of the cyclooxygenase (COX) enzyme, COX-2, is also constitutively present in the spinal cord and has been… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2004
2004
GW406381 (8), currently undergoing clinical evaluation for the treatment of inflammatory pain is a member of a novel series of 2… Expand